Try our mobile app

General information

Country: UNITED STATES

Sector: Medical Devices

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company"s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
Website: abbott.com


  • Good financial results growth rate 10.4% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (2.0%)
  • Dividend yield for the last twelve months 2.2%
  • Free cash flow yield 0.4% (LTM)
  • Share price is 20.7% higher than minimum and 22.4% lower than maximum for the last 3 years
  • The company is undervalued by EV / LTM EBITDA multiple compared to target level (21.5x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders bought company shares on $2.6 mln (0.001% of cap.)

Key Financials (Download financials)

Ticker: ABT
Share price, USD:  (-1.7%)108.83
year average price 126.97  


year start price 127.42 2025-03-19

max close price 138.08 2025-06-24

min close price 106.05 2026-01-28

current price 108.83 2026-03-18
Common stocks: 1 746 881 140

Dividend Yield:  2.2%
FCF Yield LTM: 0.4%
EV / LTM EBITDA: 21.5x
EV / EBITDA annualized: 19.7x
Last revenue growth (y/y):  +4.4%
Last growth of EBITDA (y/y):  +16.3%
Historical revenue growth:  +0.9%
Historical growth of EBITDA:  +3.0%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 190 113
Net Debt ($m): 13 587
EV (Enterprise Value): 203 700
EBITDA LTM ($m): 9 487
EV / LTM EBITDA: 21.5x
Price to Book: 3.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2026-02-04reuters.com

Abbott recalls glucose sensors after seven deaths linked to faulty readings

2026-02-04247wallst.com

5 Goldman Sachs Top Stock Picks Have Huge Upside Potential and Pay Dividends

2026-02-02seekingalpha.com

Abbott: Long-Term Investment Opportunity For Dividend Growth Investors

2026-01-31fool.com

Looking for Passive Income in 2026? 3 Dividend Kings to Buy Hand Over Fist

2026-01-25seekingalpha.com

Abbott Laboratories: Double-Digit Earnings Growth Makes It A Buy

2026-01-24marketbeat.com

Is Abbott's January Pullback a Good Time to Buy?

2026-01-24seekingalpha.com

Abbott Laboratories: The Market's Overreaction Is The Long-Term Investor's Opportunity

2026-01-23zacks.com

Abbott (ABT) is a Top-Ranked Value Stock: Should You Buy?

2026-01-23forbes.com

Is The Fall In Abbott Stock Justified?

2026-01-23seekingalpha.com

Abbott Laboratories: Buy This Dividend King On Sale Now
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data